Open AccessAre We Ready for the 10% Solution?
Author(s) -
Chen Helen X.,
Rubinstein Larry V.,
Shankar Lalitha K.,
Abrams Jeffrey S.
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0126
Subject(s) - medicine , renal cell carcinoma , response evaluation criteria in solid tumors , flexibility (engineering) , intensive care medicine , oncology , medical physics , clinical trial , phases of clinical research , statistics , mathematics
The limitations of the Response Evaluation Criteria in Solid Tumors (RECIST) for the assessment of molecularly targeted agents have been increasingly recognized with the advance of new therapies. The current study and others focusing on vascular endothelial growth factor‐pathway inhibitors in advanced renal cell carcinoma highlight that tumor shrinkage below the RECIST threshold can be associated with significant clinical benefit, and flexibility in size change categorization should be considered in future modification of the criteria.